Newsletter: MADRAC Bulletin / Archives

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 
No Document Name Type Size
15.

MADRAC Newsletter 2009 - December 

- Potential Medication Errors with Tamiflu for Oral Suspension
- Update on Oseltamivir ADRs
- Early Communication about an Ongoing Review of Orlistat (Marketed as Alli and Xenical)
- Update on Pandemrix H1N1 Vaccine
- Immunosuppressants and Increased Risk for Opportunistic Infections Such As Activation of Latent Viral Infections Including BK Virus-Associated Nephropathy
- Severe Drug Interaction Between Colchicine and P-Glycoprotein or Strong CYP3A4 Inhibitors
- Alendronates and Atypical Stress Fractures
- Hydroxycut- Withdrawal of Suspension
- Potential Risk Associated With Concomitant Use of Ceftriaxone With Calcium-containing Intravenous Solutions
- Local Case Report: Gardasil- Drug Exposure During Pregnancy

 Click to Download  0.82 MB
16.

MADRAC ADR Newsletter 2009 - August 

- Cutaneous Adverse Drug Reactions: An Overview of Local ADR Reports in 2008
- Cellcept (Mycophenolate Mofetil) and Pure Red Cell Aplasia (PRCA)
- Rapamune- Increase in Mortality in Stable Liver Transplant Patients
- Cefepime: Update of Ongoing Safety Review
- Early Communication about Safety of Lantus (insulin glargine)
- Secondary Exposure to Androgel
- Propylthiouracil (PTU)-induced Liver Failure
- Possible Interaction between Clopidogrel and Proton Pump Inhibitors
- Drug Exposure during Pregnancy- Gardasil
- Diphteria, Tetanus, Acellular Pertussis, Inactivated Poliomyelitis Vaccine, Adsorbed and Haemophilus Influenza Type B Conjugate Vaccine (Pentaxim)

Click to Download   1.42 MB
17.

 MADRAC ADR Newsletter 2009-May 

- Adverse Drug Reaction Reports for 2008- An Overview
- Ten Drugs with the Most Reported Adverse Drug Reactions
- Ten Best Reporting Hospitals
- Summary of Regulatory Actions Taken in 2008
- Oral Sodium Phosphate Products for Bowel Cleansing
- Association of Progressive Multifocal Leukoencephalopathy with Efalizumab
- Local Case Report: Goji Guarana
- Local Case Report: Tadalafil and Smell Loss

Click to Download  1.15 MB 
18.

MADRAC ADR Newsletters 2008 - December 

- Champix (Varenicline): An Update
- Stevens Johnson Syndrome and Toxic Epidermal Necrolysis Associated with the Use of Allopurinol
- Adverse Events Following Immunisation (AEFI)
- Acomplia (Rimonabant)
- Fluoroquinolones and Tendon Disorders
- Mentalk Candy

Click to Download  4.42 MB
19.

MADRAC ADR Newsletter 2008 - August 

- Safety Issues:
- Champix (Varenicline)
- Mycophenolate Mofetil (Cellcept) and Mycophenolic Acid (Myfortic)- Risk in Pregnancy
- Cefepime – Reports of Death
- Mycophenolate Mofetil (Cellcept) and Mycophenolic Acid (Myfortic) and the Development of Progressive Multifocal Leukoencephalopathy
- Use of Cough and Cold Products in Children Under Two Years Old- An Update
- Exubera (Recombinant Human Insulin) and Primary Lung Malignancy
- Incidence of Myocardial Infarction in Pregnant Women Receiving Beta Agonist to delay Premature Labour- Additional Warning and Precaution
- Low Molecular Weight Heparin- Clexane Prefilled Syringes (Enoxaparin)
- Cardiamed- An Update
- Local Case Reports:
• Drug Exposure during Pregnancy- Olanzapine
• Kisan Injection 10mg/ml
• A Reminder: Metoclopramide- Usage in Children

Click to Download  1.15 MB
20.

MADRAC ADR Newsletter 2008 - May 

- Adverse Drug Reactions (ADR) Reports for 2007 – An Overview
- Ten Drugs with the Most Reported Adverse Drug Reactions (Year 2002 – 2007)
- Ten Best Reporting Hospitals
- Summary of Regulatory Actions Taken in 2007
- Issues of Current Interest
• Severe Hyponatraemia and Seizures Associated with the Use of Desmopressin
• Botulinum Toxin
- Local Case Reports
• Tonik Warisan Banjar
• Cardiamed® (Noradrenaline) Injection

 Click to Download 1.19 MB
21.

MADRAC ADR Newsletter 2007 - September

- Ten Drugs with the Most Reported Adverse Drug Reactions (Year 2000-2006)
- Metoclopramide: Tightened Use in Paediatrics
- Antipsychotics: Reports of Neuroleptic Malignant Syndrome
- Oseltamivir: Monitor for Signs of Unusual Behaviour
- Rosiglitazone and Rosiglitazone-containing Products Update
- Gadolinium-based Contrast Agents and Nephrogenic Systemic Fibrosis
- Sedative- Hypnotic Drug Products: Anaphylaxis Reactions and Complex Sleep-related Behaviours
- Restricted Use for Systemic Piroxicam
- Local Case Report: Sticopus Horrens (Gamat Extract): Renal Failure/ Nephrotic Syndrome

Click to Download 3.10 MB
22.

MADRAC ADR Newsletter 2007 - December

- Trasylol® (Aprotinin) – Marketing Suspension
- Appropriate Use of Cough And Cold Products
- Avandia® (Rosiglitazone) – Update
- Byetta® (Exenatide) – Acute Pancreatitis
- Haloperidol – New Warning and Revised Prescription Information
- Ban on Red 2G Colouring Agent
- Deregistration of Nimesulide
- Local Case Reports
• Pediacel®
• Drug Exposure During Pregnancy - Sodium Valproate

Click to Download 0.55 MB
23.

MADRAC ADR Newsletter 2007 - May

- Overview of ADR Reporting in Malaysia for the Year 2006
- Summary of Regulatory Action Taken in 2006
- Issues of Current Interest:
• Arcoxia (Etoricoxib)
• Interaction between Tramadol and Warfarin
• Pioglitazone Hydrochloride and Risk of Bone Fracture
• Nimesulide and Hepatic Failure
• Trasylol Labelling and Risk of Renal Dysfunction
• NSAIDs- Cardiovascular, Gastrointestinal and Cutaneous Safety Review
- Reports from Journal: In-utero Case Report
- Tegaserod Maleate and Risk of Cardiovascular Adverse Events

Click to Download 1.20 MB
24.

MADRAC ADR Newsletter 2006 - December

- A study of ADRs in Malaysian Children Reported to the NPCB
- Issues of Current Interest
• 5-Hydroxytryptamine Receptor Agonists (Triptans) Selective Serotonin Reuptake Inhibitors (SSRIs) Selective Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) Serotonin Syndrome
• Incompatibilities Ceftriaxone And Calcium.
• Possible signal of depression with Ezetimibe
• Aprotinin Injection - Trasylol®
- Local Case Reports
• Switching from Ritalin to Straterra : Suspected association with priapism.
• Lenogastrim and Fatal Acute Megakaryoblastic Anemia
• Anzapine and Increased Total White Blood Cell Count
- Current Regulatory Issues
• ACE Inhibitors and “Increased Risk Of Birth Defects, Fetal And Neonatal Morbidity And Death When Used Throughout Pregnancy”
• Arginine : Warning statement on “Not Recommended For Patients Following A Heart Attack”.
- Report from Journal
• The National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifen (STAR) Trial.

Click to Download 1.40 MB
25.

MADRAC ADR Newsletter 2006 - September

- Ten Drugs with the Most Reported ADRs (Year 2000-2005)
- Issues of Current Interest
• Gadolinium and Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF/NFD)
• Raloxifene (EVISTA) Associated with Increased Risk of Death Due to Stroke.
• Lamotrigine and Risk of Oral Clefts
- Local Case Reports
• Suspected Hepatotoxicity Associated with the Use of Camellia Sinensis
• Carbimazole and Dysphagia
• Setraline and Cleft Palate
- Black Cohosh, Root: Warning Statement on Hepatotoxicity
- Promethazine and The Potential for Fatal Respiratory Depression
- Reports from Journals
• ACE Inhibitors and Congenital Anomalies
• Attention-Deficit Hyperactivity Disorder (ADHD) Drug Labels
- ADR monitoring: A Co-operative Programme for Enhancing the Safer Use of Medicines

Click to Download 0.33 MB
26.

MADRAC ADR Newsletter 2006 - March

- Overview of Adverse Drug Reactions (ADR) Reports for 2005
- Summary of Regulatory Actions Taken in 2005
- Local Case Reports
• Jamu Asam Urat Jaya Asli
• Valproic acid-induced Pancreatitis in a Child
- Issues of Current Interest
• Tibolone (LIFT study)- The Increased Risk of Stroke Outweighs the Benefit of a Decreased Risk of Vertebral Fractures

Click to Download 0.36 MB

 

 

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Newsletter Subsription

Site Last Modified

  • Last Modified: Thursday 13 December 2018, 12:14:43.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA